[{"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["quinpirole", "effect", "amphetamine"]]}, {"text": "patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.", "triple_list": [["lithium", "advise", "Neulasta"]]}, {"text": "Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["cholestyramine", "mechanism", "vitamin K"]]}, {"text": "Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["colestipol", "mechanism", "vitamin K"]]}, {"text": "Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["mineral oil", "mechanism", "vitamin K"]]}, {"text": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "triple_list": [["cefdinir", "mechanism", "Maalox TC"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "triple_list": [["probenecid", "mechanism", "cefdinir"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["cefdinir", "mechanism", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["cefdinir", "mechanism", "iron"]]}, {"text": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "triple_list": [["iron supplements", "advise", "OMNICEF"]]}, {"text": "The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "triple_list": [["cefdinir", "mechanism", "iron"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["eszopiclone", "effect", "ethanol"]]}, {"text": "Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.", "triple_list": [["eszopiclone", "effect", "olanzapine"]]}, {"text": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "triple_list": [["heparin", "effect", "Activase"]]}, {"text": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "triple_list": [["dipyridamole", "effect", "Activase"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "effect", "contraceptives"]]}, {"text": "Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.", "triple_list": [["sympathomimetics", "effect", "MAO inhibitors"]]}, {"text": "Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. ", "triple_list": [["morphine", "effect", "dmPGE2"]]}, {"text": "Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).", "triple_list": [["tamoxifen", "advise", "anastrozole"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["anastrozole", "mechanism", "tamoxifen"]]}, {"text": "Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.", "triple_list": [["meclofenamate sodium", "advise", "warfarin"]]}, {"text": "Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.", "triple_list": [["aspirin", "mechanism", "meclofenamate sodium"]]}, {"text": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "triple_list": [["cytotoxic", "effect", "PROLEUKIN"]]}, {"text": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "triple_list": [["PROLEUKIN", "effect", "tamoxifen"]]}, {"text": "Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.", "triple_list": [["PROLEUKIN", "effect", "interferon-alfa"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "effect", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["Beta-blockers", "effect", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["antihypertensives", "effect", "PROLEUKIN"]]}, {"text": "Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.", "triple_list": [["interleukin-2", "effect", "radiographic iodinated contrast media"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["MEPERIDINE", "advise", "SEDATIVE-HYPNOTICS"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["MEPERIDINE", "advise", "TRICYCLIC ANTIDEPRESSANTS"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["MEPERIDINE", "advise", "CNS DEPRESSANTS"]]}, {"text": "Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.\r\n", "triple_list": [["neurotensin", "effect", "enkephalins"]]}, {"text": "It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ", "triple_list": [["neurotensin", "effect", "enkephalins"]]}, {"text": "On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ", "triple_list": [["neurotensin", "effect", "tuftsin"]]}, {"text": "however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.", "triple_list": [["diphosphonate", "effect", "Calcitonin (salmon)"]]}, {"text": "There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.", "triple_list": [["etidronate", "effect", "warfarin"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "mechanism", "verografine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "mechanism", "iodamide"]]}, {"text": "Interaction of clindamycin and gentamicin in vitro.\n", "triple_list": [["clindamycin", "int", "gentamicin"]]}, {"text": "Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ", "triple_list": [["clindamycin", "effect", "gentamicin"]]}, {"text": "Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ", "triple_list": [["clindamycin", "effect", "gentamicin"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ", "triple_list": [["tetracyclines", "advise", "anticoagulant"]]}, {"text": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "triple_list": [["tetracyclines", "mechanism", "calcium"]]}, {"text": "The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ", "triple_list": [["tetracycline", "effect", "methoxyflurane"]]}, {"text": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "triple_list": [["tetracyclines", "effect", "contraceptives"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["methsuximide", "mechanism", "phenytoin"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "triple_list": [["ergot-type medications", "advise", "AXERT"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "triple_list": [["dihydroergotamine", "advise", "AXERT"]]}, {"text": "Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.", "triple_list": [["moclobemide", "mechanism", "almotriptan"]]}, {"text": "Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.", "triple_list": [["5-HT1B/1D agonists", "advise", "AXERT"]]}, {"text": "If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "triple_list": [["AXERT", "advise", "SSRI"]]}, {"text": "Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.", "triple_list": [["almotriptan", "mechanism", "verapamil"]]}, {"text": "Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.", "triple_list": [["almotriptan", "mechanism", "ketoconazole"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["macrolides", "int", "terfenadine"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["macrolides", "int", "astemizole"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["roxithromycin", "advise", "terfenadine"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["roxithromycin", "advise", "astemizole"]]}, {"text": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "triple_list": [["atropine sulfate", "int", "MAO inhibitors"]]}, {"text": "When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.", "triple_list": [["duloxetine", "mechanism", "desipramine"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["Duloxetine", "advise", "antidepressants"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["Duloxetine", "advise", "phenothiazines"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["Duloxetine", "advise", "Type 1C antiarrhythmics"]]}, {"text": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.", "triple_list": [["Duloxetine", "advise", "thioridazine"]]}, {"text": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "triple_list": [["ascorbic acid", "mechanism", "synthetic estrogens"]]}, {"text": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "triple_list": [["Atorvastatin", "mechanism", "norethindrone"]]}, {"text": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "triple_list": [["hormonal contraceptives", "mechanism", "benzodiazepines"]]}, {"text": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "triple_list": [["Griseofulvin", "mechanism", "combination hormonal contraceptives"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["Rifampin", "mechanism", "ethinyl estradiol"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["Rifampin", "mechanism", "progestins"]]}, {"text": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "triple_list": [["combination hormonal contraceptives", "effect", "caffeine"]]}, {"text": "Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.", "triple_list": [["anakinra", "effect", "TNF-blocking agent"]]}, {"text": "Interaction of ketamine and halothane in rats.\n", "triple_list": [["ketamine", "int", "halothane"]]}, {"text": "The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ", "triple_list": [["ketamine", "mechanism", "halothane"]]}, {"text": "It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.", "triple_list": [["ketamine", "effect", "halothane"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "effect", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["norepinephrine", "effect", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["norepinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ", "triple_list": [["Furosemide", "effect", "metolazone"]]}, {"text": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ", "triple_list": [["loop diuretics", "effect", "metolazone"]]}, {"text": "If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.", "triple_list": [["phenytoin", "mechanism", "Norpace"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["Norpace", "mechanism", "quinidine"]]}, {"text": "Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.", "triple_list": [["disopyramide phosphate", "mechanism", "erythromycin"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["disopyramide", "advise", "verapamil"]]}, {"text": "Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.", "triple_list": [["T.A.", "advise", "SSRIs"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "effect", "psychotropic agents"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "effect", "tranquilizers"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "effect", "sedative"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine", "effect", "benzodiazepines"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine", "effect", "chlordiazepoxide"]]}, {"text": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "triple_list": [["cimetidine", "mechanism", "tricyclic antidepressants"]]}, {"text": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "triple_list": [["tricyclic antidepressants", "mechanism", "cimetidine"]]}, {"text": "There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.", "triple_list": [["tricyclic antidepressants", "mechanism", "fluoxetine"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["HMG-CoA reductase inhibitors", "advise", "Fentanyl"]]}, {"text": "Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.", "triple_list": [["bepridil hydrochloride", "mechanism", "digoxin"]]}, {"text": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "triple_list": [["Amphetamines", "effect", "tricyclic antidepressants"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "desipramine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "protriptyline"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "mechanism", "tricyclics"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "effect", "amphetamines"]]}, {"text": "Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.", "triple_list": [["amphetamines", "mechanism", "methenamine"]]}, {"text": "Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.", "triple_list": [["propoxyphene", "effect", "amphetamine"]]}, {"text": "The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ", "triple_list": [["oxybutynin", "effect", "anticholinergic drugs"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["antimycotic agents", "mechanism", "oxybutynin"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["itraconazole", "mechanism", "oxybutynin"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["macrolide antibiotics", "mechanism", "oxybutynin"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["erythromycin", "mechanism", "oxybutynin"]]}, {"text": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.", "triple_list": [["Femara", "mechanism", "tamoxifen"]]}, {"text": "In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ", "triple_list": [["opioids", "mechanism", "pegvisomant"]]}, {"text": "Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.", "triple_list": [["naltrexone", "mechanism", "Acamprosate"]]}, {"text": "Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.", "triple_list": [["Acamprosate", "effect", "antidepressants"]]}, {"text": "Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.", "triple_list": [["Mefloquine", "effect", "quinidine"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["anticonvulsant", "effect", "Mefloquine"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["phenobarbital", "effect", "Mefloquine"]]}, {"text": "Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ", "triple_list": [["beta adrenergic aerosol bronchodilators", "advise", "Alupent"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["anesthetic solutions", "effect", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["anesthetic solutions", "effect", "phenothiazines"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["epinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["epinephrine", "effect", "phenothiazines"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["norepinephrine", "effect", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["norepinephrine", "effect", "phenothiazines"]]}, {"text": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "triple_list": [["vasopressor drugs", "effect", "ergot-type oxytocic drugs"]]}, {"text": "Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.", "triple_list": [["chloroprocaine", "advise", "sulfonamide drug"]]}, {"text": "Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ", "triple_list": [["InsP(3)", "effect", "RR"]]}, {"text": "Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.", "triple_list": [["Aspirin", "advise", "nonsteroidal anti-inflammatory"]]}, {"text": "Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ", "triple_list": [["alcohol", "mechanism", "mirtazapine"]]}, {"text": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ", "triple_list": [["diazepam", "mechanism", "mirtazapine"]]}, {"text": "When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ", "triple_list": [["oxandrolone", "advise", "warfarin"]]}, {"text": "Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ", "triple_list": [["warfarin", "advise", "oxandrolone"]]}, {"text": "Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ", "triple_list": [["Oxandrolone", "mechanism", "hypoglycemic agents"]]}, {"text": "The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.", "triple_list": [["ERGOMAR", "mechanism", "triacetyloleandomycin"]]}, {"text": "The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.", "triple_list": [["ERGOMAR", "effect", "vasoconstrictor drugs"]]}, {"text": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "triple_list": [["Clonidine", "effect", "barbiturates"]]}, {"text": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "triple_list": [["FACTIVE", "mechanism", "contraceptive"]]}, {"text": "Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.", "triple_list": [["FACTIVE", "mechanism", "probenecid"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["quinolones", "effect", "warfarin"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["quinolone antimicrobial", "advise", "warfarin"]]}, {"text": "The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.", "triple_list": [["gemifloxacin", "mechanism", "aluminum"]]}, {"text": "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.", "triple_list": [["thiazide diuretics", "effect", "dihydrotachysterol"]]}, {"text": "Antagonism between lincomycin and erythromycin in vitro has been demonstrated.", "triple_list": [["lincomycin", "effect", "erythromycin"]]}, {"text": "John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "triple_list": [["anticonvulsants", "mechanism", "mifepristone"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["STRATTERA", "advise", "albuterol"]]}, {"text": "In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.", "triple_list": [["paroxetine", "mechanism", "atomoxetine"]]}, {"text": "When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.", "triple_list": [["antiplatelet agents", "effect", "FLOLAN"]]}, {"text": "When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.", "triple_list": [["anticoagulants", "effect", "FLOLAN"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["furosemide", "mechanism", "FLOLAN"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "mechanism", "FLOLAN"]]}, {"text": "Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.", "triple_list": [["Targretin", "mechanism", "gemfibrozil"]]}, {"text": "Concomitant administration of gemfibrozil with Targretin capsules is not recommended.", "triple_list": [["gemfibrozil", "advise", "Targretin"]]}, {"text": "Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.", "triple_list": [["carbamazepine", "mechanism", "SUPRAX"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "triple_list": [["rifampin", "mechanism", "methylprednisolone"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "triple_list": [["rifampin", "advise", "methylprednisolone"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ", "triple_list": [["troleandomycin", "mechanism", "methylprednisolone"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ", "triple_list": [["ketoconazole", "mechanism", "methylprednisolone"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ", "triple_list": [["salicylate", "effect", "methylprednisolone"]]}, {"text": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ", "triple_list": [["DEMSER", "advise", "phenothiazines"]]}, {"text": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ", "triple_list": [["DEMSER", "advise", "haloperidol"]]}, {"text": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "triple_list": [["DEMSER", "effect", "alcohol"]]}, {"text": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "triple_list": [["DEMSER", "effect", "CNS depressants"]]}, {"text": "Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.", "triple_list": [["TCAs", "advise", "SSRIs"]]}, {"text": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.", "triple_list": [["selective serotonin reuptake inhibitors", "mechanism", "doxepin"]]}, {"text": "Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.", "triple_list": [["tricyclic antidepressant", "effect", "cimetidine"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["cimetidine", "mechanism", "tricyclic antidepressant"]]}, {"text": "Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.", "triple_list": [["alcohol", "mechanism", "SINEQUAN"]]}, {"text": "Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).", "triple_list": [["tolazamide", "effect", "doxepin"]]}, {"text": "If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.", "triple_list": [["steroid", "advise", "bitolterol"]]}, {"text": "If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.", "triple_list": [["bitolterol", "advise", "steroid"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["tricyclic antidepressants", "effect", "ELDEPRYL"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["selective serotonin reuptake inhibitors", "effect", "ELDEPRYL"]]}, {"text": "One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).", "triple_list": [["selegiline", "effect", "sympathomimetic medication"]]}, {"text": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.", "triple_list": [["antihistamines", "effect", "central nervous system depressants"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["naloxone", "effect", "beta-endorphin"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["naloxone", "effect", "beta-endorphin"]]}, {"text": "On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ", "triple_list": [["naloxone", "effect", "morphine"]]}, {"text": "Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ", "triple_list": [["naloxone", "effect", "beta-endorphin"]]}, {"text": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "triple_list": [["capecitabine", "effect", "coumarin-derivative anticoagulants"]]}, {"text": "Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).", "triple_list": [["coumarin-derivative anticoagulants", "advise", "capecitabine"]]}, {"text": "In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ", "triple_list": [["ropivacaine", "mechanism", "fluvoxamine"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ketoconazole", "mechanism", "ropivacaine"]]}, {"text": "The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).", "triple_list": [["prochlorperazine", "effect", "CAMPTOSAR"]]}, {"text": "It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.", "triple_list": [["laxative", "effect", "CAMPTOSAR"]]}, {"text": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "triple_list": [["diuretics", "effect", "CAMPTOSAR"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["4-methylpyrazole", "effect", "1,3-difluoro-2-propanol"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["4-methylpyrazole", "effect", "1,3-difluoro-2-propanol"]]}, {"text": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "triple_list": [["Factrel", "effect", "phenothiazines"]]}, {"text": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "triple_list": [["Factrel", "effect", "dopamine antagonists"]]}, {"text": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "triple_list": [["TRISENOX", "advise", "antiarrhythmics"]]}, {"text": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "triple_list": [["TRISENOX", "advise", "diuretics"]]}, {"text": "For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.", "triple_list": [["cholestyramine", "mechanism", "anticoagulants"]]}, {"text": "Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.", "triple_list": [["anticoagulants", "mechanism", "tolbutamide"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticoagulants", "mechanism", "phenytoin"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticoagulant", "mechanism", "phenytoin"]]}, {"text": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "triple_list": [["aspirin", "effect", "anticoagulants"]]}, {"text": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "triple_list": [["sulfonylureas", "effect", "azoles"]]}, {"text": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "triple_list": [["miconazole", "int", "hypoglycemic agents"]]}, {"text": "The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.", "triple_list": [["fluconazole", "int", "glipizide"]]}, {"text": "The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).", "triple_list": [["glipizide", "mechanism", "fluconazole"]]}, {"text": "If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ", "triple_list": [["ZEMURON", "advise", "succinylcholine"]]}, {"text": "Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "triple_list": [["L-tyrosine", "effect", "MAO inhibitors"]]}, {"text": "The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.", "triple_list": [["tolbutamide", "effect", "Atromid-S"]]}, {"text": "Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.", "triple_list": [["fibrate", "effect", "lovastatin"]]}, {"text": "For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.", "triple_list": [["lovastatin", "effect", "fibrate"]]}, {"text": "Therefore, the combined use of lovastatin with fibrates should generally be avoided.", "triple_list": [["lovastatin", "advise", "fibrates"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "mechanism", "didanosine"]]}, {"text": "Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ", "triple_list": [["indinavir", "mechanism", "didanosine"]]}, {"text": "Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.", "triple_list": [["Ponstel", "advise", "aspirin"]]}, {"text": "Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.", "triple_list": [["NSAIDs", "mechanism", "methotrexate"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "furosemide"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["NSAIDs", "effect", "thiazides"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["NSAIDs", "mechanism", "lithium"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["NSAIDs", "mechanism", "lithium"]]}, {"text": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["NSAIDs", "advise", "lithium"]]}, {"text": "Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.", "triple_list": [["warfarin", "effect", "NSAIDs"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["magnesium hydroxide", "mechanism", "mefenamic acid"]]}, {"text": "Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "triple_list": [["oxytocics", "effect", "dinoprost"]]}, {"text": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "triple_list": [["aspirin", "advise", "methazolamide"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["aspirin", "mechanism", "ketoprofen"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["aspirin", "mechanism", "ketoprofen"]]}, {"text": "Therefore, concurrent use of aspirin and ketoprofen is not recommended.", "triple_list": [["aspirin", "advise", "ketoprofen"]]}, {"text": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.", "triple_list": [["ketoprofen", "advise", "warfarin"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["Probenecid", "mechanism", "ketoprofen"]]}, {"text": "Therefore, the combination of ketoprofen and probenecid is not recommended.", "triple_list": [["ketoprofen", "advise", "probenecid"]]}, {"text": "Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.", "triple_list": [["Nonsteroidal anti-inflammatory agents", "mechanism", "lithium"]]}, {"text": "It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.", "triple_list": [["ketoprofen", "advise", "lithium"]]}, {"text": "however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ", "triple_list": [["nitrate", "effect", "sildenafil"]]}, {"text": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.", "triple_list": [["heparin", "effect", "Retavase"]]}, {"text": "Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.", "triple_list": [["fenoldopam", "advise", "beta-blockers"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["diltiazem hydrochloride", "mechanism", "propranolol"]]}, {"text": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.", "triple_list": [["cimetidine", "mechanism", "diltiazem"]]}, {"text": "Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.", "triple_list": [["diltiazem hydrochloride", "mechanism", "digoxin"]]}, {"text": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "advise", "diltiazem hydrochloride"]]}, {"text": "When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.", "triple_list": [["anesthetics", "advise", "calcium channel blockers"]]}, {"text": "A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.", "triple_list": [["diltiazem", "int", "cyclosporine"]]}, {"text": "If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.", "triple_list": [["cyclosporine", "advise", "diltiazem"]]}, {"text": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.", "triple_list": [["diltiazem", "mechanism", "carbamazepine"]]}, {"text": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "triple_list": [["diltiazem", "mechanism", "midazolam"]]}, {"text": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "triple_list": [["diltiazem", "mechanism", "triazolam"]]}, {"text": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.", "triple_list": [["diltiazem", "effect", "midazolam"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["diltiazem", "mechanism", "lovastatin"]]}, {"text": "Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.", "triple_list": [["rifampin", "mechanism", "diltiazem"]]}, {"text": "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.", "triple_list": [["diltiazem", "advise", "rifampin"]]}, {"text": "ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias. ", "triple_list": [["digitalis", "effect", "sympathomimetic amines"]]}, {"text": "Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.", "triple_list": [["xanthine bronchodilators", "effect", "sympathomimetic bronchodilators"]]}, {"text": "Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.", "triple_list": [["proton pump inhibitors", "effect", "warfarin"]]}, {"text": "Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).", "triple_list": [["esomeprazole", "mechanism", "iron"]]}, {"text": "Concomitant administration of clarithromycin with pimozide is contraindicated.", "triple_list": [["clarithromycin", "advise", "pimozide"]]}, {"text": "It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ", "triple_list": [["oxymorphone", "effect", "propofol"]]}, {"text": "The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.", "triple_list": [["NSAIDs", "effect", "ACE inhibitors"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["naproxen", "advise", "aspirin"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["naproxen", "advise", "aspirin"]]}, {"text": "Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.", "triple_list": [["NSAIDs", "effect", "propranolol"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["naproxen sodium", "mechanism", "methotrexate"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["NSAIDs", "mechanism", "methotrexate"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["acetaminophen", "mechanism", "BUSULFEX"]]}, {"text": "Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.", "triple_list": [["HEXALEN", "effect", "antidepressants of the MAO inhibitor class"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["HEXALEN", "effect", "cisplatin"]]}, {"text": "however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1", "triple_list": [["pyridoxine", "advise", "HEXALEN"]]}, {"text": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "triple_list": [["butorphanol", "effect", "central nervous system depressants"]]}, {"text": "However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.", "triple_list": [["STADOL NS", "mechanism", "sumatriptan"]]}, {"text": "When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.", "triple_list": [["STADOL NS", "mechanism", "sumatriptan"]]}, {"text": "These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.", "triple_list": [["STADOL NS", "effect", "sumatriptan"]]}, {"text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "triple_list": [["antipsychotic drug", "effect", "antiparkinsonian drug"]]}, {"text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "triple_list": [["antipsychotic drug", "effect", "tricyclic antidepressant"]]}, {"text": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "triple_list": [["antiparkinsonian drug", "effect", "tricyclic antidepressant"]]}, {"text": "Interactions of cobalt and iron in absorption and retention.\r\n", "triple_list": [["cobalt", "mechanism", "iron"]]}, {"text": "Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ", "triple_list": [["iron", "mechanism", "cobalt"]]}, {"text": "Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ", "triple_list": [["iron", "mechanism", "cobalt"]]}, {"text": "Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ", "triple_list": [["iron", "mechanism", "cobalt"]]}, {"text": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "triple_list": [["doxapram", "effect", "sympathomimetic"]]}, {"text": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "triple_list": [["doxapram", "effect", "monoamine oxidase inhibiting drugs"]]}, {"text": "Concomitant use of calcium supplements and L-lysine may increase calcium absorption", "triple_list": [["calcium", "mechanism", "L-lysine"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["epinephrine", "effect", "cyclopropane"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["epinephrine", "effect", "halogenated hydrocarbon general anesthetics"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["epinephrine", "effect", "halothane"]]}, {"text": "In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.", "triple_list": [["amphotericin B", "effect", "hydrocortisone"]]}, {"text": "Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.", "triple_list": [["Macrolide antibiotics", "mechanism", "corticosteroid"]]}, {"text": "Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.", "triple_list": [["anticholinesterase agents", "effect", "corticosteroids"]]}, {"text": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.", "triple_list": [["anticholinesterase agents", "advise", "corticosteroid"]]}, {"text": "Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.", "triple_list": [["corticosteroids", "effect", "warfarin"]]}, {"text": "Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.", "triple_list": [["corticosteroids", "effect", "antidiabetic agents"]]}, {"text": "Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.", "triple_list": [["cyclosporine", "effect", "corticosteroids"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["Ketoconazole", "mechanism", "corticosteroids"]]}, {"text": "In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.", "triple_list": [["ketoconazole", "effect", "corticosteroid"]]}, {"text": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.", "triple_list": [["aspirin", "effect", "corticosteroids"]]}, {"text": "Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.", "triple_list": [["phenytoin", "mechanism", "dexamethasone"]]}, {"text": "Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.", "triple_list": [["corticosteroid", "effect", "inactivated vaccines"]]}, {"text": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.", "triple_list": [["vaccines", "advise", "corticosteroid"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["beta-blockers", "advise", "clonidine"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["beta-blocker", "advise", "clonidine"]]}, {"text": "Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.", "triple_list": [["calcium antagonists", "advise", "beta-adrenergic blocking agents"]]}, {"text": "Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.", "triple_list": [["beta-adrenergic blocking agents", "effect", "calcium antagonist"]]}, {"text": "Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.", "triple_list": [["beta-blockers", "effect", "epinephrine"]]}, {"text": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "triple_list": [["ergot-type medications", "advise", "FROVA"]]}, {"text": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "triple_list": [["dihydroergotamine", "advise", "FROVA"]]}, {"text": "If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "triple_list": [["frovatriptan", "advise", "SSRI"]]}, {"text": "It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.", "triple_list": [["isoniazid", "effect", "acetaminophen"]]}, {"text": "Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.", "triple_list": [["isoniazid", "mechanism", "acetaminophen"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Isoniazid", "mechanism", "carbamazepine"]]}, {"text": "Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.", "triple_list": [["Ketoconazole", "int", "Isoniazid"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["isoniazid", "mechanism", "theophylline"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["isoniazid", "advise", "valproate"]]}, {"text": "In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.", "triple_list": [["cerivastatin sodium", "mechanism", "cholestyramine"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cholestyramine", "mechanism", "cerivastatin sodium"]]}, {"text": "While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ", "triple_list": [["ZAVESCA", "mechanism", "Cerezyme"]]}, {"text": "Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.", "triple_list": [["Cerezyme", "advise", "ZAVESCA"]]}, {"text": "Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.", "triple_list": [["erythromycin", "int", "terfenadine"]]}, {"text": "In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.", "triple_list": [["macrolides", "advise", "terfenadine"]]}, {"text": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.", "triple_list": [["dirithromycin", "mechanism", "antacids"]]}, {"text": "Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.", "triple_list": [["Erythromycin", "mechanism", "triazolam"]]}, {"text": "Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.", "triple_list": [["Erythromycin", "effect", "triazolam"]]}, {"text": "Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["erythromycin", "mechanism", "digoxin"]]}, {"text": "Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "triple_list": [["erythromycin", "effect", "anticoagulants"]]}, {"text": "Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["erythromycin", "effect", "ergotamine"]]}, {"text": "Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["erythromycin", "effect", "dihydroergotamine"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["INSPRA", "mechanism", "ketoconazole"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["eplerenone", "mechanism", "erythromycin"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["eplerenone", "mechanism", "verapamil"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["eplerenone", "mechanism", "saquinavir"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["eplerenone", "mechanism", "fluconazole"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["INSPRA", "effect", "ACE inhibitors"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["INSPRA", "effect", "angiotensin II receptor antagonists"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["INSPRA", "effect", "enalapril"]]}, {"text": "Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.", "triple_list": [["INSPRA", "advise", "lithium"]]}, {"text": "The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.", "triple_list": [["potassium-sparing antihypertensives", "effect", "NSAIDs"]]}, {"text": "Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.", "triple_list": [["INSPRA", "advise", "NSAIDs"]]}, {"text": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "triple_list": [["calcium channel blockers", "effect", "organic nitrates"]]}, {"text": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "triple_list": [["monoamine oxidase inhibitors", "effect", "serotoninergic agents"]]}, {"text": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "triple_list": [["selective serotonin reuptake inhibitors", "effect", "Imitrex"]]}, {"text": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["MYOBLOC", "advise", "aminoglycosides"]]}, {"text": "It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ", "triple_list": [["MPTP", "effect", "pargyline"]]}, {"text": "Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.", "triple_list": [["live-attenuated vaccines", "advise", "RAPTIVA"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["phenobarbital", "effect", "acetaminophen"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["valproic acid", "effect", "phenobarbital"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["FORADIL", "advise", "monoamine oxidase inhibitors"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["FORADIL", "advise", "tricyclic antidepressants"]]}, {"text": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "triple_list": [["allopurinol", "effect", "ampicillin"]]}, {"text": "It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.", "triple_list": [["ampicillin", "effect", "allopurinol"]]}, {"text": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "triple_list": [["cimetidine", "mechanism", "isradipine"]]}, {"text": "If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.", "triple_list": [["isradipine", "advise", "cimetidine"]]}, {"text": "Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.", "triple_list": [["rifampicin", "mechanism", "isradipine"]]}, {"text": "If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.", "triple_list": [["rifampicin", "mechanism", "isradipine"]]}, {"text": "Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.", "triple_list": [["fentanyl", "effect", "beta blocker"]]}, {"text": "Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.", "triple_list": [["L-phenylalanine", "effect", "non-selective MAO inhibitors"]]}, {"text": "Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.", "triple_list": [["L-phenylalanine", "effect", "selegiline"]]}, {"text": "However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.", "triple_list": [["iloprost", "effect", "vasodilators"]]}, {"text": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "triple_list": [["quinolones", "mechanism", "Videx"]]}, {"text": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "triple_list": [["quinolone class antimicrobial", "effect", "nonsteroidal anti-inflammatory drug"]]}, {"text": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "triple_list": [["quinolone class antimicrobial", "effect", "fenbufen"]]}, {"text": "Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.", "triple_list": [["cinoxacin", "advise", "nonsteroidal anti-inflammatory agents"]]}, {"text": "Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.", "triple_list": [["quinolones", "mechanism", "cyclosporine"]]}, {"text": "Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ", "triple_list": [["valproic acid", "mechanism", "temozolomide"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).", "triple_list": [["ENBREL", "effect", "anakinra"]]}, {"text": "Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).", "triple_list": [["ENBREL", "effect", "anakinra"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["sulfasalazine", "effect", "ENBREL"]]}, {"text": "However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ", "triple_list": [["TOLECTIN", "effect", "warfarin"]]}, {"text": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ", "triple_list": [["nonsteroidal anti-inflammatory drugs", "mechanism", "methotrexate"]]}, {"text": "Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.", "triple_list": [["ethoxzolamide", "effect", "corticosteroids"]]}, {"text": "conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).", "triple_list": [["diethylpropion", "int", "antihypertensive drugs"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Nicotinic acid", "effect", "ganglionic blocking agents"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["VERSED Syrup", "effect", "narcotics"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["VERSED Syrup", "effect", "meperidine"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["VERSED Syrup", "effect", "secobarbital"]]}, {"text": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "triple_list": [["nonsteroidal anti-inflammatory agents", "effect", "Starlix"]]}, {"text": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "triple_list": [["non-selective beta-adrenergic-blocking agents", "effect", "Starlix"]]}, {"text": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "triple_list": [["sympathomimetics", "effect", "Starlix"]]}, {"text": "Therefore, the coadministration of probenecid with meropenem is not recommended. ", "triple_list": [["probenecid", "advise", "meropenem"]]}, {"text": "There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).", "triple_list": [["meropenem", "mechanism", "valproic acid"]]}, {"text": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "triple_list": [["CNS depressant drugs", "None", "opioids"]]}, {"text": "The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["quinpirole", "None", "quinpirole"]]}, {"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["amphetamine", "None", "quinpirole"]]}, {"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["amphetamine", "None", "amphetamine"]]}, {"text": "In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "quinpirole"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["amphetamine", "None", "quinpirole"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["amphetamine", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["amphetamine", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["quinpirole", "None", "amphetamine"]]}, {"text": "Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ", "triple_list": [["amphetamine", "None", "amphetamine"]]}, {"text": "Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["cholestyramine", "None", "vitamin K"]]}, {"text": "Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["vitamin K", "None", "vitamin K"]]}, {"text": "Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["colestipol", "None", "vitamin K"]]}, {"text": "Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["vitamin K", "None", "vitamin K"]]}, {"text": "Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["mineral oil", "None", "vitamin K"]]}, {"text": "Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.", "triple_list": [["vitamin K", "None", "vitamin K"]]}, {"text": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "triple_list": [["cefdinir", "None", "antacid"]]}, {"text": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "triple_list": [["cefdinir", "None", "cefdinir"]]}, {"text": "There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.", "triple_list": [["antacid", "None", "cefdinir"]]}, {"text": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "triple_list": [["antacids", "None", "OMNICEF"]]}, {"text": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "triple_list": [["antacids", "None", "OMNICEF"]]}, {"text": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "triple_list": [["OMNICEF", "None", "OMNICEF"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "triple_list": [["probenecid", "None", "cefdinir"]]}, {"text": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "triple_list": [["cefdinir", "None", "cefdinir"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["Iron", "None", "cefdinir"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["Iron", "None", "iron supplement"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["Iron", "None", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["Iron", "None", "vitamins"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["Iron", "None", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["cefdinir", "None", "iron supplement"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["cefdinir", "None", "vitamins"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["iron supplement", "None", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["iron supplement", "None", "vitamins"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["iron supplement", "None", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["iron", "None", "vitamins"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["iron", "None", "iron"]]}, {"text": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "triple_list": [["vitamins", "None", "iron"]]}, {"text": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "triple_list": [["iron supplements", "None", "OMNICEF"]]}, {"text": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "triple_list": [["OMNICEF", "None", "OMNICEF"]]}, {"text": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "triple_list": [["iron", "None", "iron"]]}, {"text": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "triple_list": [["iron", "None", "cefdinir"]]}, {"text": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "triple_list": [["iron", "None", "cefdinir"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["Ethanol", "None", "eszopiclone"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["Ethanol", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["Ethanol", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["eszopiclone", "None", "ethanol"]]}, {"text": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "triple_list": [["ethanol", "None", "ethanol"]]}, {"text": "Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.", "triple_list": [["eszopiclone", "None", "paroxetine"]]}, {"text": "Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.", "triple_list": [["eszopiclone", "None", "lorazepam"]]}, {"text": "Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.", "triple_list": [["Digoxin", "None", "eszopiclone"]]}, {"text": "Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.", "triple_list": [["Digoxin", "None", "digoxin"]]}, {"text": "Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.", "triple_list": [["eszopiclone", "None", "digoxin"]]}, {"text": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "triple_list": [["heparin", "None", "dipyridamole"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["Antithrombotics", "None", "Aspirin"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["Antithrombotics", "None", "heparin"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["Antithrombotics", "None", "Activase"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["Aspirin", "None", "heparin"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["Aspirin", "None", "Activase"]]}, {"text": "Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.", "triple_list": [["heparin", "None", "Activase"]]}, {"text": "The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.", "triple_list": [["heparin", "None", "aspirin"]]}, {"text": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "triple_list": [["anticonvulsants", "None", "antituberculosis drug"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "corticotropin"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "central nervous system (CNS) depressants"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "valproic acid"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["anticoagulants", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "central nervous system (CNS) depressants"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "valproic acid"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["corticotropin", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "central nervous system (CNS) depressants"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "valproic acid"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "valproic acid"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["central nervous system (CNS) depressants", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "valproic acid"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["valproic acid", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["valproic acid", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["valproic acid", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["valproic acid", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["valproic acid", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["barbiturates", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["contraceptives", "None", "estrogens"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["contraceptives", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["contraceptives", "None", "contraceptives"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["estrogens", "None", "barbiturates"]]}, {"text": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "triple_list": [["estrogens", "None", "contraceptives"]]}, {"text": "On the other hand, the enhanced secretion of colonic fluid by dmPGE2, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of dmPGE2 in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. ", "triple_list": [["dmPGE2", "None", "dmPGE2"]]}, {"text": "Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ", "triple_list": [["amantadine", "None", "pramipexole"]]}, {"text": "Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ", "triple_list": [["pramipexole", "None", "pramipexole"]]}, {"text": "CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. ", "triple_list": [["pramipexole", "None", "pramipexole"]]}, {"text": "Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ", "triple_list": [["pramipexole", "None", "neuroleptics"]]}, {"text": "An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.", "triple_list": [["warfarin", "None", "anastrozole"]]}, {"text": "An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.", "triple_list": [["anastrozole", "None", "warfarin"]]}, {"text": "At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.", "triple_list": [["ARIMIDEX", "None", "tamoxifen"]]}, {"text": "At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.", "triple_list": [["ARIMIDEX", "None", "tamoxifen"]]}, {"text": "At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.", "triple_list": [["tamoxifen", "None", "tamoxifen"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["anastrozole", "None", "anastrozole"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["anastrozole", "None", "anastrozole"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["tamoxifen", "None", "anastrozole"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["tamoxifen", "None", "anastrozole"]]}, {"text": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "triple_list": [["anastrozole", "None", "anastrozole"]]}, {"text": "Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.", "triple_list": [["meclofenamate sodium", "None", "warfarin"]]}, {"text": "Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.", "triple_list": [["meclofenamate sodium", "None", "meclofenamate sodium"]]}, {"text": "The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.", "triple_list": [["PROLEUKIN", "None", "antineoplastic agents"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "None", "Beta-blockers"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "None", "antihypertensives"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["glucocorticoids", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "Beta-blockers"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "antihypertensives"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "Beta-blockers"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "antihypertensives"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "Beta-blockers"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "antihypertensives"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["PROLEUKIN", "None", "PROLEUKIN"]]}, {"text": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "triple_list": [["Beta-blockers", "None", "antihypertensives"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["SEDATIVE-HYPNOTICS", "None", "TRICYCLIC ANTIDEPRESSANTS"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["SEDATIVE-HYPNOTICS", "None", "CNS DEPRESSANTS"]]}, {"text": "Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL). ", "triple_list": [["TRICYCLIC ANTIDEPRESSANTS", "None", "CNS DEPRESSANTS"]]}, {"text": "The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. ", "triple_list": [["neurotensin", "None", "enkephalins"]]}, {"text": "Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.", "triple_list": [["Plenaxis", "None", "testosterone"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "None", "verografin"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "None", "iodamide"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "None", "cimetidine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "None", "verografine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["cimetidine", "None", "iodamide"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["verografin", "None", "iodamide"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["verografin", "None", "cimetidine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["verografin", "None", "verografine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["verografin", "None", "iodamide"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["iodamide", "None", "cimetidine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["iodamide", "None", "verografine"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["iodamide", "None", "iodamide"]]}, {"text": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "triple_list": [["verografine", "None", "iodamide"]]}, {"text": "The higher verografine and iodamide excretion was due to their increased renal tubular secretion. ", "triple_list": [["verografine", "None", "iodamide"]]}, {"text": "Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.", "triple_list": [["cimetidine", "None", "verografine"]]}, {"text": "Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.", "triple_list": [["cimetidine", "None", "iodamide"]]}, {"text": "Possible extrarenal mechanisms of action of cimetidine on verografine and iodamide transport were also examined.", "triple_list": [["verografine", "None", "iodamide"]]}, {"text": "The minimal inhibitory concentrations of clindamycin and gentamicin alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. ", "triple_list": [["clindamycin", "None", "gentamicin"]]}, {"text": "All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both clindamycin (minimal inhibitory concentration greater than 3.1 mug/ml) and gentamicin (minimal inhibitory concentration greater than 6.2 mug/ml). ", "triple_list": [["clindamycin", "None", "gentamicin"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ", "triple_list": [["tetracyclines", "None", "anticoagulant"]]}, {"text": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ", "triple_list": [["anticoagulant", "None", "anticoagulant"]]}, {"text": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "triple_list": [["tetracyclines", "None", "antacids"]]}, {"text": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ", "triple_list": [["antacids", "None", "calcium"]]}, {"text": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "triple_list": [["tetracyclines", "None", "contraceptives"]]}, {"text": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "triple_list": [["contraceptives", "None", "contraceptives"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["Celontin", "None", "methsuximide"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["Celontin", "None", "methsuximide"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["Celontin", "None", "phenytoin"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["methsuximide", "None", "methsuximide"]]}, {"text": "Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).", "triple_list": [["methsuximide", "None", "phenytoin"]]}, {"text": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "triple_list": [["ergot-type medications", "None", "dihydroergotamine"]]}, {"text": "Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.", "triple_list": [["5-HT1B/1D Agonists", "None", "5-HT1B/1D agonists"]]}, {"text": "Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.", "triple_list": [["5-HT1B/1D Agonists", "None", "AXERT"]]}, {"text": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "triple_list": [["SSRIs", "None", "SSRIs"]]}, {"text": "Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.", "triple_list": [["almotriptan", "None", "almotriptan"]]}, {"text": "Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.", "triple_list": [["verapamil", "None", "almotriptan"]]}, {"text": "Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.", "triple_list": [["almotriptan", "None", "almotriptan"]]}, {"text": "Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.", "triple_list": [["ketoconazole", "None", "almotriptan"]]}, {"text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "triple_list": [["almotriptan", "None", "almotriptan"]]}, {"text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "triple_list": [["almotriptan", "None", "almotriptan"]]}, {"text": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "triple_list": [["almotriptan", "None", "almotriptan"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["Terfenadine", "None", "astemizole"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["Terfenadine", "None", "macrolides"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["Terfenadine", "None", "terfenadine"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["Terfenadine", "None", "astemizole"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["astemizole", "None", "macrolides"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["astemizole", "None", "terfenadine"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["astemizole", "None", "astemizole"]]}, {"text": "Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ", "triple_list": [["terfenadine", "None", "astemizole"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["roxithromycin", "None", "roxithromycin"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["roxithromycin", "None", "terfenadine"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["roxithromycin", "None", "astemizole"]]}, {"text": "Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ", "triple_list": [["terfenadine", "None", "astemizole"]]}, {"text": "Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.", "triple_list": [["roxithromycin", "None", "roxithromycin"]]}, {"text": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "triple_list": [["atropine sulfate", "None", "diphenoxylate hydrochloride"]]}, {"text": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "triple_list": [["MAO inhibitors", "None", "diphenoxylate hydrochloride"]]}, {"text": "Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.", "triple_list": [["duloxetine", "None", "duloxetine"]]}, {"text": "Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.", "triple_list": [["duloxetine", "None", "duloxetine"]]}, {"text": "Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.", "triple_list": [["duloxetine", "None", "duloxetine"]]}, {"text": "Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.", "triple_list": [["duloxetine", "None", "duloxetine"]]}, {"text": "Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.", "triple_list": [["Duloxetine", "None", "duloxetine"]]}, {"text": "When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.", "triple_list": [["duloxetine", "None", "desipramine"]]}, {"text": "When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.", "triple_list": [["desipramine", "None", "desipramine"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["antidepressants", "None", "phenothiazines"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["antidepressants", "None", "Type 1C antiarrhythmics"]]}, {"text": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "triple_list": [["phenothiazines", "None", "Type 1C antiarrhythmics"]]}, {"text": "Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.", "triple_list": [["thioridazine", "None", "Duloxetine"]]}, {"text": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.", "triple_list": [["thioridazine", "None", "thioridazine"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["Duloxetine", "None", "Duloxetine"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["Duloxetine", "None", "ethanol"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["Duloxetine", "None", "Duloxetine"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["Duloxetine", "None", "ethanol"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["Duloxetine", "None", "Duloxetine"]]}, {"text": "Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.", "triple_list": [["ethanol", "None", "Duloxetine"]]}, {"text": "In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.", "triple_list": [["Duloxetine", "None", "Duloxetine"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["Duloxetine", "None", "antacids"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["Duloxetine", "None", "Duloxetine"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["Duloxetine", "None", "duloxetine"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["antacids", "None", "Duloxetine"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["antacids", "None", "duloxetine"]]}, {"text": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "triple_list": [["Duloxetine", "None", "duloxetine"]]}, {"text": "It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.", "triple_list": [["proton pump inhibitors", "None", "duloxetine"]]}, {"text": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "triple_list": [["Atorvastatin", "None", "Atorvastatin"]]}, {"text": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "triple_list": [["Atorvastatin", "None", "norethindrone"]]}, {"text": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "triple_list": [["Griseofulvin", "None", "Griseofulvin"]]}, {"text": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "triple_list": [["Griseofulvin", "None", "combination hormonal contraceptives"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["Rifampin", "None", "Rifampin"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["Rifampin", "None", "ethinyl estradiol"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["Rifampin", "None", "progestins"]]}, {"text": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "triple_list": [["ethinyl estradiol", "None", "progestins"]]}, {"text": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "triple_list": [["caffeine", "None", "combination hormonal contraceptives"]]}, {"text": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "triple_list": [["caffeine", "None", "caffeine"]]}, {"text": "Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;", "triple_list": [["ethinyl estradiol", "None", "progesterone"]]}, {"text": "The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.", "triple_list": [["anakinra", "None", "HUMIRA"]]}, {"text": "The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. ", "triple_list": [["ketamine", "None", "halothane"]]}, {"text": "The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. ", "triple_list": [["ketamine", "None", "ketamine"]]}, {"text": "The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ", "triple_list": [["ketamine", "None", "ketamine"]]}, {"text": "The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ", "triple_list": [["halothane", "None", "ketamine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "epinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "monoamine oxidase inhibitors"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["anesthetic solutions", "None", "tricyclic antidepressants"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["epinephrine", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "triple_list": [["monoamine oxidase inhibitors", "None", "tricyclic antidepressants"]]}, {"text": "Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "triple_list": [["vasopressor drugs", "None", "ergot-type oxytocic drugs"]]}, {"text": "Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes. ", "triple_list": [["Furosemide", "None", "loop diuretics"]]}, {"text": "If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.", "triple_list": [["phenytoin", "None", "disopyramide"]]}, {"text": "If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.", "triple_list": [["Norpace", "None", "disopyramide"]]}, {"text": "In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.", "triple_list": [["Norpace", "None", "propranolol"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["Norpace", "None", "disopyramide"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["Norpace", "None", "quinidine"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["quinidine", "None", "disopyramide"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["quinidine", "None", "quinidine"]]}, {"text": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "triple_list": [["disopyramide", "None", "quinidine"]]}, {"text": "Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.", "triple_list": [["disopyramide phosphate", "None", "disopyramide"]]}, {"text": "Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.", "triple_list": [["erythromycin", "None", "disopyramide"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["verapamil", "None", "disopyramide phosphate"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["verapamil", "None", "disopyramide"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["verapamil", "None", "verapamil"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["disopyramide phosphate", "None", "disopyramide"]]}, {"text": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "triple_list": [["disopyramide phosphate", "None", "verapamil"]]}, {"text": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "triple_list": [["SSRI", "None", "SSRI"]]}, {"text": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "None", "desipramine"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "None", "benzodiazepines"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["desipramine hydrochloride", "None", "chlordiazepoxide"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["psychotropic agents", "None", "tranquilizers"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["psychotropic agents", "None", "sedative"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["psychotropic agents", "None", "desipramine"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["psychotropic agents", "None", "benzodiazepines"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["psychotropic agents", "None", "chlordiazepoxide"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["tranquilizers", "None", "sedative"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["tranquilizers", "None", "desipramine"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["tranquilizers", "None", "benzodiazepines"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["tranquilizers", "None", "chlordiazepoxide"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["sedative", "None", "desipramine"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["sedative", "None", "benzodiazepines"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["sedative", "None", "chlordiazepoxide"]]}, {"text": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "triple_list": [["benzodiazepines", "None", "chlordiazepoxide"]]}, {"text": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "triple_list": [["cimetidine", "None", "tricyclic antidepressants"]]}, {"text": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressants"]]}, {"text": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "triple_list": [["cimetidine", "None", "tricyclic antidepressant"]]}, {"text": "Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.", "triple_list": [["daptomycin", "None", "warfarin"]]}, {"text": "There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.", "triple_list": [["simvastatin", "None", "daptomycin"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "Fentanyl"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["HMG-CoA reductase inhibitors", "None", "Fentanyl"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["Fentanyl", "None", "HMG-CoA reductase inhibitors"]]}, {"text": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "triple_list": [["Fentanyl", "None", "Fentanyl"]]}, {"text": "Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.", "triple_list": [["Bepridil", "None", "nitrates"]]}, {"text": "Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.", "triple_list": [["nitroglycerin", "None", "Bepridil"]]}, {"text": "Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.", "triple_list": [["Bepridil", "None", "beta-blocking agents"]]}, {"text": "Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.", "triple_list": [["bepridil hydrochloride", "None", "digoxin"]]}, {"text": "Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.", "triple_list": [["Bepridil", "None", "insulin"]]}, {"text": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "triple_list": [["anti-arrhythmic agents", "None", "quinidine"]]}, {"text": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "triple_list": [["anti-arrhythmic agents", "None", "cardiac glycosides"]]}, {"text": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "triple_list": [["quinidine", "None", "cardiac glycosides"]]}, {"text": "Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.", "triple_list": [["Adrenergic blockers", "None", "Adrenergic blockers"]]}, {"text": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "triple_list": [["tricyclic", "None", "Amphetamines"]]}, {"text": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "triple_list": [["tricyclic", "None", "tricyclic antidepressants"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["d-amphetamine", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "protriptyline"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "tricyclics"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["desipramine", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["protriptyline", "None", "tricyclics"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["protriptyline", "None", "d-amphetamine"]]}, {"text": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "triple_list": [["tricyclics", "None", "d-amphetamine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "Chlorpromazine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "amphetamines"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "amphetamine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["Chlorpromazine", "None", "amphetamine"]]}, {"text": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "triple_list": [["amphetamines", "None", "amphetamine"]]}, {"text": "Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.", "triple_list": [["Haloperidol", "None", "Haloperidol"]]}, {"text": "Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ", "triple_list": [["oxybutynin chloride", "None", "DITROPAN XL"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["antimycotic agents", "None", "itraconazole"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["antimycotic agents", "None", "macrolide antibiotics"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["antimycotic agents", "None", "erythromycin"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["itraconazole", "None", "macrolide antibiotics"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["itraconazole", "None", "erythromycin"]]}, {"text": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ", "triple_list": [["macrolide antibiotics", "None", "erythromycin"]]}, {"text": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ", "triple_list": [["antacid", "None", "antacid"]]}, {"text": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ", "triple_list": [["antacid", "None", "oxybutynin"]]}, {"text": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ", "triple_list": [["antacid", "None", "oxybutynin"]]}, {"text": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "triple_list": [["Cimetidine", "None", "Cimetidine"]]}, {"text": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "triple_list": [["Cimetidine", "None", "fosfomycin"]]}, {"text": "Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.", "triple_list": [["Cimetidine", "None", "fosfomycin"]]}, {"text": "Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.", "triple_list": [["cimetidine", "None", "warfarin"]]}, {"text": "Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.", "triple_list": [["cimetidine", "None", "Femara"]]}, {"text": "Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.", "triple_list": [["warfarin", "None", "Femara"]]}, {"text": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.", "triple_list": [["Femara", "None", "letrozole"]]}, {"text": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.", "triple_list": [["tamoxifen", "None", "letrozole"]]}, {"text": "Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ", "triple_list": [["insulin", "None", "hypoglycemic"]]}, {"text": "In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ", "triple_list": [["opioids", "None", "opioids"]]}, {"text": "In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ", "triple_list": [["pegvisomant", "None", "opioids"]]}, {"text": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.", "triple_list": [["alcohol", "None", "Acamprosate"]]}, {"text": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.", "triple_list": [["alcohol", "None", "alcohol"]]}, {"text": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.", "triple_list": [["Acamprosate", "None", "alcohol"]]}, {"text": "Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.", "triple_list": [["disulfiram", "None", "diazepam"]]}, {"text": "The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.", "triple_list": [["naltrexone", "None", "6-beta-naltrexol"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["Acamprosate", "None", "hypnotics"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["Acamprosate", "None", "sedatives"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["Acamprosate", "None", "non-opioid analgesics"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["hypnotics", "None", "sedatives"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["hypnotics", "None", "non-opioid analgesics"]]}, {"text": "Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.", "triple_list": [["sedatives", "None", "non-opioid analgesics"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["amantadine", "None", "antiarrhythmic agents"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["amantadine", "None", "antihistamines"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["amantadine", "None", "antipsychotic agents"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["antiarrhythmic agents", "None", "antihistamines"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["antiarrhythmic agents", "None", "antipsychotic agents"]]}, {"text": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "triple_list": [["antihistamines", "None", "antipsychotic agents"]]}, {"text": "MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.", "triple_list": [["narcotic analgesics", "None", "nitrates"]]}, {"text": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "triple_list": [["anti-arrhythmic", "None", "antihistamines"]]}, {"text": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "triple_list": [["anti-arrhythmic", "None", "tricyclic antidepressants"]]}, {"text": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "triple_list": [["antihistamines", "None", "tricyclic antidepressants"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["anticonvulsant", "None", "phenobarbital"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["anticonvulsant", "None", "anticonvulsant"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["phenobarbital", "None", "anticonvulsant"]]}, {"text": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "triple_list": [["Mefloquine", "None", "anticonvulsant"]]}, {"text": "In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.", "triple_list": [["sulfadoxine", "None", "pyrimethamine"]]}, {"text": "Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.", "triple_list": [["monoamine oxidase inhibitors", "None", "beta adrenergic agonists"]]}, {"text": "Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.", "triple_list": [["digoxin", "None", "warfarin"]]}, {"text": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "triple_list": [["eprosartan", "None", "ketoconazole"]]}, {"text": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "triple_list": [["eprosartan", "None", "eprosartan"]]}, {"text": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "triple_list": [["ketoconazole", "None", "eprosartan"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["anesthetic solutions", "None", "epinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["anesthetic solutions", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["epinephrine", "None", "norepinephrine"]]}, {"text": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "triple_list": [["tricyclic antidepressants", "None", "phenothiazines"]]}, {"text": "The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ", "triple_list": [["ruthenium red", "None", "inositol 1,4,5-trisphosphate"]]}, {"text": "Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.", "triple_list": [["aspirin", "None", "salicylate"]]}, {"text": "While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ", "triple_list": [["mirtazapine", "None", "mirtazapine"]]}, {"text": "While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ", "triple_list": [["mirtazapine", "None", "REMERON SolTab"]]}, {"text": "While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ", "triple_list": [["mirtazapine", "None", "REMERON SolTab"]]}, {"text": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ", "triple_list": [["alcohol", "None", "diazepam"]]}, {"text": "Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ", "triple_list": [["alcohol", "None", "mirtazapine"]]}, {"text": "Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ", "triple_list": [["S-warfarin", "None", "R-warfarin"]]}, {"text": "A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ", "triple_list": [["oxandrolone", "None", "warfarin"]]}, {"text": "When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ", "triple_list": [["hypoglycemic agents", "None", "Oxandrolone"]]}, {"text": "Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ", "triple_list": [["hypoglycemic agents", "None", "hypoglycemic agents"]]}, {"text": "Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ", "triple_list": [["ACTH", "None", "adrenal cortical steroids"]]}, {"text": "Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ", "triple_list": [["ACTH", "None", "ACTH"]]}, {"text": "Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ", "triple_list": [["adrenal cortical steroids", "None", "ACTH"]]}, {"text": "Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.", "triple_list": [["clonidine hydrochloride", "None", "clonidine"]]}, {"text": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "triple_list": [["clonidine", "None", "Clonidine"]]}, {"text": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "triple_list": [["clonidine", "None", "barbiturates"]]}, {"text": "Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.", "triple_list": [["clonidine", "None", "clonidine"]]}, {"text": "Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.", "triple_list": [["FACTIVE", "None", "digoxin"]]}, {"text": "Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.", "triple_list": [["FACTIVE", "None", "contraceptive product"]]}, {"text": "Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.", "triple_list": [["digoxin", "None", "contraceptive product"]]}, {"text": "FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["quinolones", "None", "quinolone antimicrobial"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["quinolones", "None", "warfarin"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["warfarin", "None", "quinolone antimicrobial"]]}, {"text": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.", "triple_list": [["gemifloxacin", "None", "antacid"]]}, {"text": "The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.", "triple_list": [["antacid", "None", "aluminum"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["ferrous sulfate", "None", "multivitamin preparations"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["ferrous sulfate", "None", "zinc"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["ferrous sulfate", "None", "Videx"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["multivitamin preparations", "None", "zinc"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["multivitamin preparations", "None", "Videx"]]}, {"text": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "triple_list": [["zinc", "None", "Videx"]]}, {"text": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ", "triple_list": [["mifepristone", "None", "mifepristone"]]}, {"text": "John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "triple_list": [["anticonvulsants", "None", "mifepristone"]]}, {"text": "John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ", "triple_list": [["mifepristone", "None", "mifepristone"]]}, {"text": "The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.", "triple_list": [["fulvestrant", "None", "fulvestrant"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["Albuterol", "None", "STRATTERA"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["Albuterol", "None", "albuterol"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["Albuterol", "None", "albuterol"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["STRATTERA", "None", "albuterol"]]}, {"text": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "triple_list": [["albuterol", "None", "albuterol"]]}, {"text": "In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.", "triple_list": [["paroxetine", "None", "atomoxetine"]]}, {"text": "In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.", "triple_list": [["atomoxetine", "None", "atomoxetine"]]}, {"text": "When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.", "triple_list": [["antiplatelet agents", "None", "anticoagulants"]]}, {"text": "However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.", "triple_list": [["FLOLAN", "None", "anticoagulants"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "FLOLAN"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "FLOLAN"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["furosemide", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["furosemide", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["furosemide", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "furosemide"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["FLOLAN", "None", "digoxin"]]}, {"text": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "triple_list": [["furosemide", "None", "digoxin"]]}, {"text": "However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "triple_list": [["bexarotene", "None", "bexarotene"]]}, {"text": "Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.", "triple_list": [["Targretin", "None", "gemfibrozil"]]}, {"text": "Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.", "triple_list": [["gemfibrozil", "None", "gemfibrozil"]]}, {"text": "Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.", "triple_list": [["bexarotene", "None", "atorvastatin"]]}, {"text": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ", "triple_list": [["methylprednisolone", "None", "methylprednisolone"]]}, {"text": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ", "triple_list": [["troleandomycin", "None", "ketoconazole"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ", "triple_list": [["salicylate", "None", "salicylate"]]}, {"text": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ", "triple_list": [["salicylate", "None", "methylprednisolone"]]}, {"text": "The effect of methylprednisolone on oral anticoagulants is variable. ", "triple_list": [["methylprednisolone", "None", "anticoagulants"]]}, {"text": "Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ", "triple_list": [["phenothiazines", "None", "haloperidol"]]}, {"text": "Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.", "triple_list": [["alcohol", "None", "CNS depressants"]]}, {"text": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "triple_list": [["Type 1C antiarrhythmics", "None", "propafenone"]]}, {"text": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "triple_list": [["SSRI", "None", "SSRI"]]}, {"text": "Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "triple_list": [["TCA", "None", "TCA"]]}, {"text": "Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.", "triple_list": [["Cimetidine", "None", "Cimetidine"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["tricyclic antidepressants", "None", "cimetidine"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["tricyclic antidepressants", "None", "cimetidine"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["tricyclic antidepressants", "None", "tricyclic antidepressant"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["cimetidine", "None", "cimetidine"]]}, {"text": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "triple_list": [["cimetidine", "None", "tricyclic antidepressant"]]}, {"text": "The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.", "triple_list": [["cyclophosphamide", "None", "cyclophosphamide"]]}, {"text": "In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ", "triple_list": [["terbinafine", "None", "antipyrine"]]}, {"text": "There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ", "triple_list": [["terbinafine", "None", "LAMISIL"]]}, {"text": "If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.", "triple_list": [["steroid", "None", "steroid"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["tricyclic antidepressants", "None", "selective serotonin reuptake inhibitors"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["tricyclic antidepressants", "None", "ELDEPRYL"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["ELDEPRYL", "None", "selective serotonin reuptake inhibitors"]]}, {"text": "Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL. ", "triple_list": [["ELDEPRYL", "None", "ELDEPRYL"]]}, {"text": "Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.\r\n", "triple_list": [["naloxone", "None", "beta-endorphin"]]}, {"text": "Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.\r\n", "triple_list": [["naloxone", "None", "morphine"]]}, {"text": "Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.\r\n", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. ", "triple_list": [["naloxone", "None", "beta-endorphin"]]}, {"text": "The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. ", "triple_list": [["naloxone", "None", "morphine"]]}, {"text": "The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. ", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. ", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["naloxone", "None", "naloxone"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["naloxone", "None", "beta-endorphin"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["beta-endorphin", "None", "naloxone"]]}, {"text": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "triple_list": [["beta-endorphin", "None", "beta-endorphin"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["beta-endorphin", "None", "beta-endorphin"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["morphine", "None", "beta-endorphin"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["morphine", "None", "morphine"]]}, {"text": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "triple_list": [["beta-endorphin", "None", "morphine"]]}, {"text": "Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.", "triple_list": [["antacid", "None", "capecitabine"]]}, {"text": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "triple_list": [["capecitabine", "None", "warfarin"]]}, {"text": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "triple_list": [["coumarin-derivative anticoagulants", "None", "warfarin"]]}, {"text": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "triple_list": [["Ropivacaine", "None", "Ropivacaine"]]}, {"text": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "triple_list": [["Ropivacaine", "None", "ropivacaine"]]}, {"text": "Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ", "triple_list": [["Ropivacaine", "None", "ropivacaine"]]}, {"text": "Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. ", "triple_list": [["theophylline", "None", "imipramine"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ketoconazole", "None", "ropivacaine"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ketoconazole", "None", "ketoconazole"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ropivacaine", "None", "ketoconazole"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ropivacaine", "None", "ropivacaine"]]}, {"text": "Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.", "triple_list": [["ketoconazole", "None", "ropivacaine"]]}, {"text": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "triple_list": [["CAMPTOSAR", "None", "diuretics"]]}, {"text": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "triple_list": [["CAMPTOSAR", "None", "CAMPTOSAR"]]}, {"text": "Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted 1,3-difluoroacetone to (-)-erythro-fluorocitrate in vitro. ", "triple_list": [["1,3-difluoroacetone", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "Administration of 1,3-difluoroacetone (100 mg kg(-1) body weight) to rats in vivo resulted in (-)-erythro-fluorocitrate synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. ", "triple_list": [["1,3-difluoroacetone", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoroacetone", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoroacetone"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoro-2-propanol", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoro-2-propanol"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoroacetone", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["1,3-difluoroacetone", "None", "1,3-difluoro-2-propanol"]]}, {"text": "We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. ", "triple_list": [["(-)-erythro-fluorocitrate", "None", "1,3-difluoro-2-propanol"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["4-methylpyrazole", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["4-methylpyrazole", "None", "1,3-difluoro-2-propanol"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["1,3-difluoro-2-propanol", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoro-2-propanol"]]}, {"text": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "triple_list": [["(-)-erythro-fluorocitrate", "None", "1,3-difluoro-2-propanol"]]}, {"text": "However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. ", "triple_list": [["4-methylpyrazole", "None", "1,3-difluoroacetone"]]}, {"text": "However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. ", "triple_list": [["4-methylpyrazole", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to 1,3-difluoroacetone (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. ", "triple_list": [["1,3-difluoroacetone", "None", "(-)-erythro-fluorocitrate"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["4-methylpyrazole", "None", "1,3-difluoro-2-propanol"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["4-methylpyrazole", "None", "1,3-difluoroacetone"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoro-2-propanol"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoroacetone"]]}, {"text": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "triple_list": [["1,3-difluoro-2-propanol", "None", "1,3-difluoroacetone"]]}, {"text": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "triple_list": [["phenothiazines", "None", "dopamine antagonists"]]}, {"text": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "triple_list": [["antiarrhythmics", "None", "diuretics"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticoagulants", "None", "anticonvulsant"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticoagulants", "None", "anticoagulant"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticoagulants", "None", "phenytoin"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["phenytoin", "None", "anticonvulsant"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["phenytoin", "None", "anticoagulant"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["phenytoin", "None", "phenytoin"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticonvulsant", "None", "anticoagulant"]]}, {"text": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "triple_list": [["anticonvulsant", "None", "phenytoin"]]}, {"text": "In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.", "triple_list": [["glipizide", "None", "tolbutamide"]]}, {"text": "In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.", "triple_list": [["glipizide", "None", "salicylate"]]}, {"text": "In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.", "triple_list": [["tolbutamide", "None", "salicylate"]]}, {"text": "All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.", "triple_list": [["glipizide", "None", "fluconazole"]]}, {"text": "If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ", "triple_list": [["ZEMURON", "None", "succinylcholine"]]}, {"text": "If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ", "triple_list": [["succinylcholine", "None", "succinylcholine"]]}, {"text": "The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ", "triple_list": [["ZEMURON", "None", "succinylcholine"]]}, {"text": "Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "triple_list": [["pargyline", "None", "L-tyrosine"]]}, {"text": "Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "triple_list": [["pargyline", "None", "MAO inhibitors"]]}, {"text": "Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.", "triple_list": [["phenytoin", "None", "tolbutamide"]]}, {"text": "While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.", "triple_list": [["fibrates", "None", "fibrates"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["indinavir", "None", "IDV"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["indinavir", "None", "IDV"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["IDV", "None", "didanosine"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["IDV", "None", "IDV"]]}, {"text": "If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.\r\n", "triple_list": [["didanosine", "None", "IDV"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["didanosine", "None", "indinavir"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["didanosine", "None", "didanosine"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["didanosine", "None", "indinavir"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "triple_list": [["didanosine", "None", "indinavir"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "indinavir"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "triple_list": [["indinavir", "None", "didanosine"]]}, {"text": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "triple_list": [["furosemide", "None", "thiazides"]]}, {"text": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["NSAIDs", "None", "lithium"]]}, {"text": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["antacid", "None", "magnesium hydroxide"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["antacid", "None", "mefenamic acid"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["antacid", "None", "mefenamic acid"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["antacid", "None", "lovastatin"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["magnesium hydroxide", "None", "mefenamic acid"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["magnesium hydroxide", "None", "lovastatin"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["mefenamic acid", "None", "mefenamic acid"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["mefenamic acid", "None", "lovastatin"]]}, {"text": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "triple_list": [["mefenamic acid", "None", "lovastatin"]]}, {"text": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.", "triple_list": [["methazolamide", "None", "aspirin"]]}, {"text": "The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.", "triple_list": [["Orudis", "None", "ketoprofen"]]}, {"text": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.", "triple_list": [["magnesium hydroxide", "None", "aluminum hydroxide"]]}, {"text": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.", "triple_list": [["magnesium hydroxide", "None", "ketoprofen"]]}, {"text": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.", "triple_list": [["aluminum hydroxide", "None", "ketoprofen"]]}, {"text": "Aspirin: Ketoprofen does not alter aspirin absorption;", "triple_list": [["Ketoprofen", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["ketoprofen", "None", "ketoprofen"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["ketoprofen", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["ketoprofen", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["ketoprofen", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["ketoprofen", "None", "aspirin"]]}, {"text": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["ketoprofen", "None", "digoxin"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["ketoprofen", "None", "ketoprofen"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["ketoprofen", "None", "digoxin"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["digoxin", "None", "ketoprofen"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "triple_list": [["ketoprofen", "None", "digoxin"]]}, {"text": "Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.", "triple_list": [["ketoprofen", "None", "warfarin"]]}, {"text": "Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.", "triple_list": [["warfarin", "None", "ketoprofen"]]}, {"text": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.", "triple_list": [["ketoprofen", "None", "ketoprofen"]]}, {"text": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.", "triple_list": [["ketoprofen", "None", "warfarin"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["Probenecid", "None", "Probenecid"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["Probenecid", "None", "ketoprofen"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["Probenecid", "None", "ketoprofen"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["Probenecid", "None", "ketoprofen"]]}, {"text": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "triple_list": [["ketoprofen", "None", "ketoprofen"]]}, {"text": "It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.", "triple_list": [["lithium", "None", "ketoprofen"]]}, {"text": "It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.", "triple_list": [["idoxuridine", "None", "idoxuridine"]]}, {"text": "METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, Viagra, and erectile dysfunction. ", "triple_list": [["sildenafil", "None", "sildenafil"]]}, {"text": "RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). ", "triple_list": [["Sildenafil", "None", "selective serotonin reuptake inhibitors"]]}, {"text": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.", "triple_list": [["fenoldopam", "None", "digitalis"]]}, {"text": "There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).", "triple_list": [["antihypertensive agents", "None", "diuretics"]]}, {"text": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.", "triple_list": [["beta-blockers", "None", "digitalis"]]}, {"text": "Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.", "triple_list": [["diltiazem hydrochloride", "None", "beta-blockers"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["diltiazem hydrochloride", "None", "propranolol"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["diltiazem hydrochloride", "None", "propranolol"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.", "triple_list": [["diltiazem", "None", "cimetidine"]]}, {"text": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.", "triple_list": [["diltiazem", "None", "diltiazem"]]}, {"text": "Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.", "triple_list": [["diltiazem hydrochloride", "None", "digoxin"]]}, {"text": "Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.", "triple_list": [["digoxin", "None", "diltiazem hydrochloride"]]}, {"text": "In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.", "triple_list": [["cyclosporine", "None", "diltiazem"]]}, {"text": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.", "triple_list": [["diltiazem", "None", "carbamazepine"]]}, {"text": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "triple_list": [["midazolam", "None", "triazolam"]]}, {"text": "The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.", "triple_list": [["midazolam", "None", "triazolam"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["diltiazem", "None", "lovastatin"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["diltiazem", "None", "lovastatin"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["lovastatin", "None", "lovastatin"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["lovastatin", "None", "lovastatin"]]}, {"text": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "triple_list": [["lovastatin", "None", "lovastatin"]]}, {"text": "no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.", "triple_list": [["pravastatin", "None", "diltiazem"]]}, {"text": "Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.", "triple_list": [["rifampin", "None", "diltiazem"]]}, {"text": "Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.", "triple_list": [["diltiazem", "None", "diltiazem"]]}, {"text": "Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .", "triple_list": [["dyphylline", "None", "dyphylline"]]}, {"text": "Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.", "triple_list": [["esomeprazole", "None", "clarithromycin"]]}, {"text": "Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.", "triple_list": [["warfarin", "None", "esomeprazole"]]}, {"text": "The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ", "triple_list": [["CNS depressants", "None", "alcohol"]]}, {"text": "Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.", "triple_list": [["sulfonamide", "None", "sulfonylurea"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["naproxen", "None", "naproxen"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["naproxen", "None", "aspirin"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["aspirin", "None", "naproxen"]]}, {"text": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "triple_list": [["aspirin", "None", "aspirin"]]}, {"text": "Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["naproxen sodium", "None", "NSAIDs"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["naproxen sodium", "None", "methotrexate"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["NSAIDs", "None", "methotrexate"]]}, {"text": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed analgesic agents and some are analgesic adjuvants as well.", "triple_list": [["analgesic agents", "None", "analgesic adjuvants"]]}, {"text": "Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.", "triple_list": [["5-HT3 antiemetics", "None", "ondansetron"]]}, {"text": "Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.", "triple_list": [["5-HT3 antiemetics", "None", "granisetron"]]}, {"text": "Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.", "triple_list": [["ondansetron", "None", "granisetron"]]}, {"text": "Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.", "triple_list": [["BUSULFEX", "None", "BUSULFEX"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["busulfan", "None", "acetaminophen"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["busulfan", "None", "BUSULFEX"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["busulfan", "None", "busulfan"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["busulfan", "None", "acetaminophen"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["acetaminophen", "None", "busulfan"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["BUSULFEX", "None", "busulfan"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["BUSULFEX", "None", "acetaminophen"]]}, {"text": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "triple_list": [["busulfan", "None", "acetaminophen"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["HEXALEN", "None", "pyridoxine"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["HEXALEN", "None", "pyridoxine"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["cisplatin", "None", "pyridoxine"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["cisplatin", "None", "pyridoxine"]]}, {"text": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "triple_list": [["pyridoxine", "None", "pyridoxine"]]}, {"text": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "triple_list": [["butorphanol", "None", "central nervous system depressant"]]}, {"text": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "triple_list": [["central nervous system depressants", "None", "central nervous system depressant"]]}, {"text": "In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.", "triple_list": [["butorphanol", "None", "STADOL NS"]]}, {"text": "However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.", "triple_list": [["butorphanol", "None", "STADOL NS"]]}, {"text": "However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.", "triple_list": [["butorphanol", "None", "sumatriptan"]]}, {"text": "When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.", "triple_list": [["STADOL NS", "None", "butorphanol"]]}, {"text": "When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.", "triple_list": [["sumatriptan", "None", "butorphanol"]]}, {"text": "The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.", "triple_list": [["STADOL NS", "None", "IMITREX"]]}, {"text": "The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).", "triple_list": [["butorphanol", "None", "STADOL NS"]]}, {"text": "The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).", "triple_list": [["butorphanol", "None", "cimetidine"]]}, {"text": "The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).", "triple_list": [["STADOL NS", "None", "cimetidine"]]}, {"text": "Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.", "triple_list": [["STADOL NS", "None", "butorphanol"]]}, {"text": "The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.", "triple_list": [["STADOL NS", "None", "nasal vasoconstrictor"]]}, {"text": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "triple_list": [["beta-blockers", "None", "narcotic"]]}, {"text": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "triple_list": [["beta-blockers", "None", "antihistamines"]]}, {"text": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "triple_list": [["narcotic", "None", "antihistamines"]]}, {"text": "The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. ", "triple_list": [["cobalt", "None", "Co"]]}, {"text": "The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. ", "triple_list": [["cobalt", "None", "Fe"]]}, {"text": "The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. ", "triple_list": [["Co", "None", "Fe"]]}, {"text": "Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ", "triple_list": [["cobalt", "None", "cobalt"]]}, {"text": "The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ", "triple_list": [["Fe", "None", "Fe"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["cobalt", "None", "iron"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["cobalt", "None", "cobalt"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["cobalt", "None", "iron"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["iron", "None", "cobalt"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["iron", "None", "iron"]]}, {"text": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "triple_list": [["cobalt", "None", "iron"]]}, {"text": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "triple_list": [["sympathomimetic", "None", "monoamine oxidase inhibiting drugs"]]}, {"text": "Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.", "triple_list": [["UROXATRAL", "None", "alpha-blockers"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["moclobemide", "None", "clonazepam"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["moclobemide", "None", "fluoxetine"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["moclobemide", "None", "sertraline"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["clonazepam", "None", "fluoxetine"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["clonazepam", "None", "sertraline"]]}, {"text": "Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ", "triple_list": [["fluoxetine", "None", "sertraline"]]}, {"text": "An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. ", "triple_list": [["glucose", "None", "glucose"]]}, {"text": "Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. ", "triple_list": [["moclobemide", "None", "glucose"]]}, {"text": "In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. ", "triple_list": [["glucose", "None", "glucose"]]}, {"text": "Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. ", "triple_list": [["sertraline", "None", "glucose"]]}, {"text": "Concomitant use of calcium supplements and L-lysine may increase calcium absorption", "triple_list": [["calcium", "None", "calcium"]]}, {"text": "Concomitant use of calcium supplements and L-lysine may increase calcium absorption", "triple_list": [["L-lysine", "None", "calcium"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["cyclopropane", "None", "halogenated hydrocarbon general anesthetics"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["cyclopropane", "None", "halothane"]]}, {"text": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "triple_list": [["halogenated hydrocarbon general anesthetics", "None", "halothane"]]}, {"text": "Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.", "triple_list": [["Aminoglutethimide", "None", "Aminoglutethimide"]]}, {"text": "Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.", "triple_list": [["corticosteroids", "None", "warfarin"]]}, {"text": "Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.", "triple_list": [["Cholestyramine", "None", "Cholestyramine"]]}, {"text": "Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.", "triple_list": [["Ephedrine", "None", "Ephedrine"]]}, {"text": "Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.", "triple_list": [["Ephedrine", "None", "corticosteroid"]]}, {"text": "Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.", "triple_list": [["Ephedrine", "None", "corticosteroid"]]}, {"text": "Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.", "triple_list": [["Estrogens", "None", "Estrogens"]]}, {"text": "Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.", "triple_list": [["corticosteroids", "None", "corticosteroid"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["Ketoconazole", "None", "corticosteroids"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["Ketoconazole", "None", "corticosteroid"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["Ketoconazole", "None", "corticosteroid"]]}, {"text": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "triple_list": [["corticosteroids", "None", "corticosteroid"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["Kerlone", "None", "anticoagulant"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["Kerlone", "None", "warfarin"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["Kerlone", "None", "warfarin"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["anticoagulant", "None", "warfarin"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["anticoagulant", "None", "warfarin"]]}, {"text": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["beta-blockers", "None", "beta-blocker"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["beta-blockers", "None", "clonidine"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["clonidine", "None", "beta-blocker"]]}, {"text": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "triple_list": [["clonidine", "None", "clonidine"]]}, {"text": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.", "triple_list": [["calcium antagonist", "None", "verapamil"]]}, {"text": "Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.", "triple_list": [["beta-blockers", "None", "beta-blockers"]]}, {"text": "Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.", "triple_list": [["epinephrine", "None", "beta-blockers"]]}, {"text": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "triple_list": [["ergot-type medications", "None", "dihydroergotamine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "Isoniazid"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "Carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "anticonvulsant"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Isoniazid", "None", "Carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Isoniazid", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Isoniazid", "None", "anticonvulsant"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["carbamazepine", "None", "Carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["carbamazepine", "None", "anticonvulsant"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "carbamazepine"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["Carbamazepine", "None", "anticonvulsant"]]}, {"text": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "triple_list": [["carbamazepine", "None", "anticonvulsant"]]}, {"text": "Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.", "triple_list": [["Ketoconazole", "None", "Ketoconazole"]]}, {"text": "Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.", "triple_list": [["Ketoconazole", "None", "Isoniazid"]]}, {"text": "To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.", "triple_list": [["phenytoin", "None", "anticonvulsant"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["isoniazid", "None", "theophylline"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["isoniazid", "None", "isoniazid"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["theophylline", "None", "isoniazid"]]}, {"text": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "triple_list": [["theophylline", "None", "isoniazid"]]}, {"text": "Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["valproate", "None", "isoniazid"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["isoniazid", "None", "valproate"]]}, {"text": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "triple_list": [["valproate", "None", "valproate"]]}, {"text": "CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.", "triple_list": [["cholestyramine", "None", "cerivastatin sodium"]]}, {"text": "In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.", "triple_list": [["cerivastatin sodium", "None", "cerivastatin sodium"]]}, {"text": "In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.", "triple_list": [["cholestyramine", "None", "cerivastatin sodium"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cholestyramine", "None", "cerivastatin"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cholestyramine", "None", "cerivastatin sodium"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cerivastatin sodium", "None", "cerivastatin"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cerivastatin sodium", "None", "cerivastatin sodium"]]}, {"text": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "triple_list": [["cerivastatin", "None", "cerivastatin sodium"]]}, {"text": "Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.", "triple_list": [["cerivastatin sodium", "None", "cholestyramine"]]}, {"text": "Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.", "triple_list": [["cerivastatin sodium", "None", "cerivastatin sodium"]]}, {"text": "Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.", "triple_list": [["cholestyramine", "None", "cerivastatin sodium"]]}, {"text": "DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "triple_list": [["warfarin", "None", "cerivastatin"]]}, {"text": "WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.", "triple_list": [["cerivastatin", "None", "warfarin"]]}, {"text": "Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.", "triple_list": [["warfarin", "None", "cerivastatin"]]}, {"text": "OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.", "triple_list": [["cerivastatin sodium", "None", "nonsteroidal anti-inflammatory drugs"]]}, {"text": "While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ", "triple_list": [["ZAVESCA", "None", "Cerezyme"]]}, {"text": "While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ", "triple_list": [["Cerezyme", "None", "Cerezyme"]]}, {"text": "These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.", "triple_list": [["terfenadine", "None", "dirithromycin"]]}, {"text": "These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.", "triple_list": [["terfenadine", "None", "dirithromycin"]]}, {"text": "The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.", "triple_list": [["terfenadine", "None", "terfenadine"]]}, {"text": "Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.", "triple_list": [["dirithromycin", "None", "theophylline"]]}, {"text": "Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.", "triple_list": [["dirithromycin", "None", "theophylline"]]}, {"text": "Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["dirithromycin", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["dirithromycin", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["dirithromycin", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.", "triple_list": [["dirithromycin", "None", "dirithromycin"]]}, {"text": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.", "triple_list": [["antacids", "None", "dirithromycin"]]}, {"text": "Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.", "triple_list": [["triazolam", "None", "triazolam"]]}, {"text": "Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["erythromycin", "None", "digoxin"]]}, {"text": "Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "triple_list": [["ergotamine", "None", "dihydroergotamine"]]}, {"text": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "triple_list": [["psychoactive drugs", "None", "barbiturates"]]}, {"text": "The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.\r\n", "triple_list": [["DCG-IV", "None", "L-CCG-1"]]}, {"text": "The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.\r\n", "triple_list": [["DCG-IV", "None", "phencyclidine"]]}, {"text": "The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.\r\n", "triple_list": [["L-CCG-1", "None", "phencyclidine"]]}, {"text": "Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. ", "triple_list": [["DCG-IV", "None", "PCP"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["INSPRA", "None", "eplerenone"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["INSPRA", "None", "eplerenone"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["ketoconazole", "None", "eplerenone"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["ketoconazole", "None", "eplerenone"]]}, {"text": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "triple_list": [["eplerenone", "None", "eplerenone"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["eplerenone", "None", "eplerenone"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["erythromycin", "None", "verapamil"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["erythromycin", "None", "saquinavir"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["erythromycin", "None", "fluconazole"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["erythromycin", "None", "eplerenone"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["verapamil", "None", "saquinavir"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["verapamil", "None", "fluconazole"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["verapamil", "None", "eplerenone"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["saquinavir", "None", "fluconazole"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["saquinavir", "None", "eplerenone"]]}, {"text": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "triple_list": [["fluconazole", "None", "eplerenone"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "INSPRA"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "ACE inhibitors"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "angiotensin II receptor antagonists"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["INSPRA", "None", "ACE inhibitors"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["INSPRA", "None", "angiotensin II receptor antagonists"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "triple_list": [["ACE inhibitors", "None", "angiotensin II receptor antagonists"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "INSPRA"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "ACE inhibitors"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["Angiotensin II Receptor Antagonists", "None", "angiotensin II receptor antagonists"]]}, {"text": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "triple_list": [["ACE inhibitors", "None", "angiotensin II receptor antagonists"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["INSPRA", "None", "ACE inhibitor"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["INSPRA", "None", "enalapril"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["ACE inhibitor", "None", "enalapril"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["ACE inhibitor", "None", "enalapril"]]}, {"text": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "triple_list": [["enalapril", "None", "enalapril"]]}, {"text": "Lithium-A drug interaction study of eplerenone with lithium has not been conducted.", "triple_list": [["eplerenone", "None", "lithium"]]}, {"text": "Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "INSPRA"]]}, {"text": "Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.", "triple_list": [["lithium", "None", "lithium"]]}, {"text": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.", "triple_list": [["eplerenone", "None", "NSAID"]]}, {"text": "Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.", "triple_list": [["dexfenfluramine", "None", "dexfenfluramine"]]}, {"text": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["MYOBLOC", "None", "toxin"]]}, {"text": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "triple_list": [["aminoglycosides", "None", "toxin"]]}, {"text": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "triple_list": [["decongestant drugs", "None", "NSAIDs"]]}, {"text": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "triple_list": [["decongestant drugs", "None", "Aleve"]]}, {"text": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "triple_list": [["NSAIDs", "None", "Aleve"]]}, {"text": "The neurochemical and functional consequences following MPTP administration to the rat were evaluated and compared to similar effects following methamphetamine administration. ", "triple_list": [["MPTP", "None", "methamphetamine"]]}, {"text": "The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ", "triple_list": [["amphetamine", "None", "apomorphine"]]}, {"text": "Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.", "triple_list": [["entecavir", "None", "BARACLUDE"]]}, {"text": "Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.", "triple_list": [["entecavir", "None", "entecavir"]]}, {"text": "Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.", "triple_list": [["BARACLUDE", "None", "entecavir"]]}, {"text": "Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.", "triple_list": [["entecavir", "None", "tenofovir disoproxil fumarate"]]}, {"text": "The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.", "triple_list": [["BARACLUDE", "None", "BARACLUDE"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "phenobarbital"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "acetaminophen"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "valproic acid"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "phenobarbital"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["phenobarbital", "None", "valproic acid"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["phenobarbital", "None", "phenobarbital"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "valproic acid"]]}, {"text": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "triple_list": [["acetaminophen", "None", "phenobarbital"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["FORADIL", "None", "formoterol"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["monoamine oxidase inhibitors", "None", "tricyclic antidepressants"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["monoamine oxidase inhibitors", "None", "formoterol"]]}, {"text": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "triple_list": [["tricyclic antidepressants", "None", "formoterol"]]}, {"text": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "triple_list": [["Methylxanthines", "None", "diuretics"]]}, {"text": "Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).", "triple_list": [["beta2-agonist", "None", "salbutamol"]]}, {"text": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "triple_list": [["allopurinol", "None", "ampicillin"]]}, {"text": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "triple_list": [["ampicillin", "None", "ampicillin"]]}, {"text": "However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.", "triple_list": [["AUGMENTIN XR", "None", "allopurinol"]]}, {"text": "Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.", "triple_list": [["DynaCirc", "None", "hydrochlorothiazide"]]}, {"text": "In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.", "triple_list": [["isradipine", "None", "hydrochlorothiazide"]]}, {"text": "In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.", "triple_list": [["hydrochlorothiazide", "None", "isradipine"]]}, {"text": "Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.", "triple_list": [["propranolol", "None", "isradipine"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "isradipine"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "isradipine"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["isradipine", "None", "propranolol"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["isradipine", "None", "propranolol"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "propranolol"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "isradipine"]]}, {"text": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "triple_list": [["propranolol", "None", "isradipine"]]}, {"text": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "triple_list": [["cimetidine", "None", "isradipine"]]}, {"text": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.", "triple_list": [["rifampicin", "None", "isradipine"]]}, {"text": "Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.", "triple_list": [["rifampicin", "None", "isradipine"]]}, {"text": "If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["isradipine", "None", "warfarin"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["isradipine", "None", "warfarin"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["isradipine", "None", "isradipine"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["warfarin", "None", "warfarin"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["warfarin", "None", "isradipine"]]}, {"text": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "triple_list": [["warfarin", "None", "isradipine"]]}, {"text": "Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.", "triple_list": [["warfarin", "None", "isradipine"]]}, {"text": "Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.", "triple_list": [["DynaCirc", "None", "digoxin"]]}, {"text": "Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.", "triple_list": [["DynaCirc", "None", "digoxin"]]}, {"text": "Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.", "triple_list": [["digoxin", "None", "digoxin"]]}, {"text": "Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.", "triple_list": [["tranylcypromine sulfate", "None", "pargyline"]]}, {"text": "Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.", "triple_list": [["L-phenylalanine", "None", "selective MAO inhibitor"]]}, {"text": "Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.", "triple_list": [["selective MAO inhibitor", "None", "selegiline"]]}, {"text": "Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.", "triple_list": [["L-phenylalanine", "None", "neuroleptic drugs"]]}, {"text": "Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.", "triple_list": [["theophylline", "None", "theophylline"]]}, {"text": "Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.", "triple_list": [["cinoxacin", "None", "cinoxacin"]]}, {"text": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "triple_list": [["quinolones", "None", "multivitamins"]]}, {"text": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "triple_list": [["multivitamins", "None", "Videx"]]}, {"text": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "triple_list": [["nonsteroidal anti-inflammatory drug", "None", "fenbufen"]]}, {"text": "Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.", "triple_list": [["cyclosporine", "None", "quinolones"]]}, {"text": "Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.", "triple_list": [["cyclosporine", "None", "cyclosporine"]]}, {"text": "However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.", "triple_list": [["ENBREL", "None", "methotrexate"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).", "triple_list": [["ENBREL", "None", "ENBREL"]]}, {"text": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).", "triple_list": [["anakinra", "None", "ENBREL"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["sulfasalazine", "None", "ENBREL"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["sulfasalazine", "None", "sulfasalazine"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["ENBREL", "None", "ENBREL"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["ENBREL", "None", "sulfasalazine"]]}, {"text": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "triple_list": [["ENBREL", "None", "sulfasalazine"]]}, {"text": "The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ", "triple_list": [["warfarin", "None", "tolmetin"]]}, {"text": "The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ", "triple_list": [["warfarin", "None", "tolmetin"]]}, {"text": "The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ", "triple_list": [["tolmetin", "None", "tolmetin"]]}, {"text": "In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ", "triple_list": [["sulfonylureas", "None", "insulin"]]}, {"text": "In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ", "triple_list": [["sulfonylureas", "None", "TOLECTIN"]]}, {"text": "In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ", "triple_list": [["insulin", "None", "TOLECTIN"]]}, {"text": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ", "triple_list": [["nonsteroidal anti-inflammatory drugs", "None", "methotrexate"]]}, {"text": "TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ", "triple_list": [["methotrexate", "None", "methotrexate"]]}, {"text": "Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.\r\n", "triple_list": [["buforin II", "None", "azithromycin"]]}, {"text": "Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.\r\n", "triple_list": [["buforin II", "None", "minocycline"]]}, {"text": "Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.\r\n", "triple_list": [["azithromycin", "None", "minocycline"]]}, {"text": "The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ", "triple_list": [["buforin II", "None", "azithromycin"]]}, {"text": "The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ", "triple_list": [["buforin II", "None", "minocycline"]]}, {"text": "The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ", "triple_list": [["azithromycin", "None", "minocycline"]]}, {"text": "Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. ", "triple_list": [["azithromycin", "None", "minocycline"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Vitamin B3", "None", "Antihypertensive"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Vitamin B3", "None", "Nicotinic acid"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Vitamin B3", "None", "ganglionic blocking agents"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Antihypertensive", "None", "Nicotinic acid"]]}, {"text": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "triple_list": [["Antihypertensive", "None", "ganglionic blocking agents"]]}, {"text": "Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ", "triple_list": [["fluconazole", "None", "itraconazole"]]}, {"text": "Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ", "triple_list": [["ritonavir", "None", "nelfinavir"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["narcotics", "None", "meperidine"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["narcotics", "None", "secobarbital"]]}, {"text": "The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ", "triple_list": [["meperidine", "None", "secobarbital"]]}, {"text": "Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.", "triple_list": [["Starlix", "None", "glyburide"]]}, {"text": "Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.", "triple_list": [["Starlix", "None", "metformin"]]}, {"text": "Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.", "triple_list": [["Starlix", "None", "digoxin"]]}, {"text": "Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.", "triple_list": [["Starlix", "None", "warfarin"]]}, {"text": "Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.", "triple_list": [["Starlix", "None", "diclofenac"]]}, {"text": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "triple_list": [["metformin", "None", "nateglinide"]]}, {"text": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "triple_list": [["nateglinide", "None", "tolbutamide"]]}, {"text": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "triple_list": [["nonsteroidal anti-inflammatory agents", "None", "non-selective beta-adrenergic-blocking agents"]]}, {"text": "Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem. ", "triple_list": [["meropenem", "None", "meropenem"]]}]